Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management

被引:10
作者
Ohyama, Manabu [1 ]
Matsudo, Kiichi [2 ]
Fujita, Toru [2 ]
机构
[1] Kyorin Univ, Fac Med, Dept Dermatol, 6-20-2 Shinkawa, Mitaka, Tokyo 1810004, Japan
[2] Taisho Pharmaceut Co Ltd, Clin Dev Res & Dev Headquarters Self Medicat, Tokyo, Japan
关键词
alopecia; COVID-19; minoxidil; pandemic; quarantine; APOPTOSIS; MINOXIDIL;
D O I
10.1111/1346-8138.16475
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a pandemic by the World Health Organization, and COVID-19 continues to have a major impact on society. Numerous studies have reported impaired health sequelae after COVID-19 recovery, one of which is hair loss. Individuals with hair loss experience a substantial mental burden, which potentially hinders their social life. However, few studies have systematically analyzed the details including hair loss. Therefore, we conducted a narrative review using PubMed on the frequency, associated comorbidities, disease characteristics, and treatment of hair loss after SARS-CoV-2 infection (HLASCI). Two search strings were used to identify 28 articles. Of note, most of the literature identified on COVID-19 sequelae reported an emergence/occurrence of hair loss. HLASCI is speculated to be composed of a heterogeneous population, with the onset or exacerbation of telogen effluvium (TE), anagen effluvium, androgenetic alopecia (AGA), and alopecia areata (AA) reported as possible underlying mechanisms. Among these, acute TE is thought to be the primary cause of HLASCI, with COVID-19 treatment and TE improvement being considered crucial for HLASCI management. An association between COVID-19 and AA exacerbation has also been implicated with still insufficient evidence. Spontaneous recovery of TE can be expected once infection reduces; however, faster improvement in symptoms is expected to reduce the mental and social burden of patients. An additional search string identified 11 articles about TE treatment which suggested that the use of minoxidil may be beneficial. Topical minoxidil has been widely used for AGA patients, who have been speculated to exhibit poor resistance to SARS-CoV-2. Topical minoxidil may provide relief from HLASCI, but future clinical research is warranted to confirm this observation.
引用
收藏
页码:939 / 947
页数:9
相关论文
共 43 条
[11]   Telogen effluvium [J].
Grover, Chander ;
Khurana, Ananta .
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2013, 79 (05) :591-603
[12]   The shifting preferences of patients and physicians in nonsurgical hair loss treatment [J].
Gupta, Aditya K. ;
Quinlan, Emma M. ;
Williams, Ken L. .
JOURNAL OF COSMETIC DERMATOLOGY, 2021, 20 (03) :929-936
[13]   Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle [J].
Han, JH ;
Kwon, OS ;
Chung, JH ;
Cho, KH ;
Eun, HC ;
Kim, KH .
JOURNAL OF DERMATOLOGICAL SCIENCE, 2004, 34 (02) :91-98
[14]   Topical odorant application of the specific olfactory receptor OR2AT4 agonist, Sandalore(R), improves telogen effluvium-associated parameters [J].
Jimenez, Francisco ;
Lopez, Esmeralda ;
Bertolini, Marta ;
Alam, Majid ;
Cheret, Jeremy ;
Westgate, Gill ;
Rinaldi, Fabio ;
Marzani, Barbara ;
Paus, Ralf .
JOURNAL OF COSMETIC DERMATOLOGY, 2021, 20 (03) :784-791
[15]   Relative changes in the pattern of diseases presenting in dermatology outpatient clinic in the era of theCOVID-19 pandemic [J].
Kutlu, Omer ;
Metin, Ahmet .
DERMATOLOGIC THERAPY, 2020, 33 (06)
[16]   Analysis of dermatologic conditions in Turkey and Italy by using Google Trends analysis in the era of theCOVID-19 pandemic [J].
Kutlu, Omer .
DERMATOLOGIC THERAPY, 2020, 33 (06)
[17]  
Lengg N., 2007, THERAPY, V4, P59, DOI [10.2217/14750708.4.1.59, DOI 10.2217/14750708.4.1.59]
[18]  
Liyanage D., 2016, COSMETICS-BASEL, V3, DOI [10.3390/cosmetics3020013, DOI 10.3390/COSMETICS3020013]
[19]  
Lopez-Leon S, 2021, SCI REP-UK, V11, DOI [10.1038/s41598-021-95565-8, 10.21203/rs.3.rs-266574/v1, 10.1101/2021.01.27.21250617]
[20]   Telogen Effluvium: A Review [J].
Malkud, Shashikant .
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2015, 9 (09) :WE1-WE3